2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Expert faculty review and share their insights and perspectives on key findings in acute and chronic leukemias presented at the 2020 ASH Annual Meeting.
Jorge Cortes, MD
Eunice S. Wang, MD

Acute and Chronic Leukemias

Expert faculty review and share their insights and perspectives on key studies on the management of acute and chronic leukemias presented at the virtual Hematology 2020 annual meeting.

Jorge Cortes, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 12, 2021 Expired: February 11, 2022

In this commentary, 2 experts discuss their top presentation choices from ASH 2020 in acute and chronic leukemias with the most potential to impact practice.

Jorge Cortes, MD Eunice S. Wang, MD Released: March 3, 2021

Experts discuss results and implications from 3 of the key studies in acute myeloid leukemia and chronic myeloid leukemia from the virtual Hematology 2020 meeting, including magrolimab in AML, the STAMP inhibitor asciminib in CML (the ASCEMBL trial), and optimal dosing for ponatinib in CML (the OPTIC trial).

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue